Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Leukemia Clinical Trial

Official title:

A Phase II Trial of IV Busulfan (Busulfex) and Melphalan as a Preparatory Regimen Prior to Allogeneic Bone Marrow Transplantation for the Treatment of Advanced and High Risk Hematologic Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00014469
• Other study ID #: 00-126
• Secondary ID: P30CA008748P01CA
• Status: Completed
• Phase: Phase 2
• First received: April 10, 2001
• Last updated: March 6, 2013
• Start date: December 2000
• Est. completion date: May 2007

Study information

• Verified date: March 2013
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of busulfan and melphalan followed by donor bone marrow transplantation in treating patients who have advanced hematologic cancer.

Description:

OBJECTIVES:

• Determine the antileukemic potential of busulfan and melphalan prior to allogeneic bone marrow transplantation in patients with advanced or high-risk hematologic malignancy.

• Determine the incidence of transplantation-related morbidity and mortality in patients treated with this regimen.

• Determine the incidence of acute and chronic graft-versus-host disease in patients treated with this regimen.

OUTLINE: Patients receive cytoreductive chemotherapy comprising busulfan IV over 2 hours every 6 hours for a total of 16 doses on days -8 to -5 and melphalan IV over 30 minutes on days -4 to -2. Patients undergo T-cell replete allogeneic bone marrow transplantation on day

0. For graft-versus-host disease prophylaxis, patients receive tacrolimus IV continuously or every 12 hours beginning on day -1 and continuing for 50 days to 6 months followed by a taper. Once oral medications are tolerated, patients switch to oral tacrolimus every 12 hours. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

Patients are followed weekly through day 100, every 6 weeks for 3 months, every 3 months for 1 year, and then every 3-6 months for 6 months.

PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 3 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: May 2007
• Est. primary completion date: May 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of one of the following:

• Infant leukemia

• Acute lymphoblastic leukemia in 3rd or greater remission or relapse

• Undifferentiated or biphenotypic leukemia in 2nd or greater remission or relapse

• Juvenile chronic myelogenous leukemia (CML)

• Acute myelogenous leukemia (AML) in 3rd or greater remission or relapse

• Primary advanced myelodysplastic syndrome (MDS) excluding refractory anemia (RA) and RA with ringed sideroblasts

• Therapy-related MDS of any stage or AML

• CML in 2nd or greater chronic phase, accelerated, or blastic phase

• Acute leukemia, CML, or MDS but unable to tolerate total body irradiation (TBI) due to potential neurotoxicity (prior TBI, prior local radiotherapy,or under 2 years of age)

• No active CNS disease

• Related or unrelated bone marrow donor matched at HLA-A, B, and DR beta 1

PATIENT CHARACTERISTICS:

Age:

• Under 60 (over 60 considered on case-by-case basis)

Performance status:

• Karnofsky 70-100%

• Lansky 70-100%

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• AST and ALT less than 2 times upper limit of normal

• Bilirubin less than 1.5 mg/dL unless liver is involved with disease

Renal:

• Creatinine normal

• Creatinine clearance greater than 60 mL/min

Cardiovascular:

• Asymptomatic with no prior risk factors OR

• LVEF greater than 50% if symptomatic

Pulmonary:

• Asymptomatic with no prior risk factors OR

• Diffusion capacity greater than 50% predicted (corrected for hemoglobin) if symptomatic

Other:

• No active uncontrolled viral, bacterial, or fungal infection

• Not pregnant or nursing

• Negative pregnancy test

• HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• More than 6 months since prior allogeneic or autologous stem cell transplantation

Chemotherapy:

• Not specified

Endocrine therapy:

• Not specified

Radiotherapy:

• See Disease Characteristics

Surgery:

• Not specified

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

• Graft Versus Host Disease
• Graft vs Host Disease
• Leukemia
• Myelodysplastic Syndromes
• Myelodysplastic-Myeloproliferative Diseases
• Myelodysplastic/Myeloproliferative Neoplasms
• Myeloproliferative Disorders
• Preleukemia

Intervention

Drug:
• busulfan

• melphalan

• methotrexate

• tacrolimus

Procedure:
• allogeneic bone marrow transplantation

Locations

Country	Name	City	State
United States	Memorial Sloan-Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States,